Guidance on the scientific requirements for health claims related to muscle function and physical performance
(Revision 1)

EFSA Panel on Nutrition, Novel Foods and Food Allergens (EFSA NDA Panel),
Dominique Turck, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-Ernst,
John Kearney, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle,
Androniki Naska, Carmen Pelaez, Kristina Pentieva, Frank Thies, Sophia Tsabouri,
Marco Vinceti, Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait,
Marina Heinonen, Monika Neuhäuser-Berthold, Grażyna Nowicka, Yolanda Sanz,
Anders Sjödin, Martin Stern, Daniel Tomé, Henk Van Loveren, Peter Willatts, Ambroise Martin,
John Joseph Strain, Leng Heng, Silvia Valtuena Martinez and Alfonso Siani

Abstract
EFSA has asked the Panel on Nutrition, Novel Foods and Food Allergens (NDA) to update the guidance on the scientific requirements for health claims related to physical performance published in 2012. The update takes into account the experience gained by the NDA Panel with the evaluation of additional health claim applications, changes introduced to the general scientific guidance for stakeholders for health claims applications and information collected from a grant launched in 2014 which aimed at gathering information in relation to claimed effects, outcome variables and methods of measurement in the context of the scientific substantiation of health claims. The guidance is intended to assist applicants in preparing applications for the authorisation of health claims related to muscle function and physical performance. The draft guidance was subject to public consultation from 16 July to 2 September 2018. This document supersedes the guidance on the scientific requirements for health claims related to physical performance published in 2012. It is intended that the guidance will be further updated as appropriate in the light of experience gained from the evaluation of health claims.

© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

Keywords: guidance, health claims, scientific requirements, muscle function, physical performance

Requestor: EFSA

Question number: EFSA-Q-2018-00243

Correspondence: nda@efsa.europa.eu
Panel members: Dominique Turck, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-Ernst, John Kearney, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marco Vinceti.

Suggested citation: EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), Turck D, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Kearney J, Knutsen HK, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Thies F, Tsabouri S, Vinceti M, Bresson J-L, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Neuhausser-Berthold M, Nowicka G, Sanz Y, Sjödin A, Stern M, Tomé D, Van Loveren H, Willatts P, Martin A, Strain JJ, Heng L, Valtueña Martínez S and Siani A, 2018. Guidance on the scientific requirements for health claims related to muscle function and physical performance (Revision 1). EFSA Journal 2018;16(10):5434, 21 pp. https://doi.org/10.2903/j.efsa.2018.5434

ISSN: 1831-4732

© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union.
Summary

The European Food Safety Authority (EFSA) has asked the Panel on Nutrition, Novel Foods and Food Allergens (NDA) to revise the guidance on the scientific requirements for health claims related to physical performance published in 2012.

Since then, the NDA Panel has completed the evaluation of Article 13.1 claims (except for claims put on hold by the European Commission) and has evaluated additional health claim applications submitted pursuant to Article 13(5) in the area covered by this guidance. In addition, the NDA Panel has developed the general scientific guidance for stakeholders for health claims applications which addresses general issues that are common to all health claims. To further assist applicants, EFSA launched in 2014 a grant which aimed at gathering information in relation to claimed effects, outcome variables and methods of measurement in the context of the scientific substantiation of health claims. The information collected helped the NDA Panel in updating the present guidance.

This guidance is intended to assist applicants in preparing applications for the authorisation of health claims related to muscle function and physical performance. It focuses on key issues, particularly:

- claimed effects which are considered to be beneficial physiological effects,
- definition of the target population for which the claim is intended;
- characteristics of the human intervention studies which can provide evidence for the scientific substantiation of specific claims addressed in this guidance (e.g. appropriate outcome variables and methods of measurement, suitable study group(s), suitable controls).

This guidance does not intend to:

- a) provide an exhaustive list of beneficial physiological effects and studies/outcome variables which could be acceptable for claim substantiation, or
- b) address potential health relationships and related outcome variables/methods of measurement which have not yet been considered by the Panel in the context of a particular application.

The draft guidance was released for public consultation (from 16 July to 2 September 2018) to gather views from scientific communities and stakeholders before finalisation. This guidance supersedes the guidance on the scientific requirements for health claims related to physical performance published in 2012. It is intended that the guidance will be further updated as appropriate in the light of experience gained from the evaluation of health claims in this area.
# Table of contents

Abstract.................................................................................................................................................... 1  
Summary.................................................................................................................................................. 3  
Background and Terms of Reference as provided by EFSA................................................................. 5  
1. Introduction....................................................................................................................................... 5  
2. Objectives and scope......................................................................................................................... 6  
3. Definition of terms............................................................................................................................ 7  
4. Assessment........................................................................................................................................ 9  
4.1. Function claims based on the essentiality of nutrients ................................................................. 9  
4.1.1. Claims on muscle function........................................................................................................... 9  
4.2. Function claims other than those based on the essentiality of nutrients ....................................... 10  
4.2.1. Claims on muscle function........................................................................................................... 10  
4.2.2. Claims on physical performance and physical capacity............................................................... 12  
4.2.2.1. Claims on physical performance................................................................................................... 12  
4.2.2.2. Claims on physical capacity ......................................................................................................... 14  
References................................................................................................................................................ 15  
Abbreviations............................................................................................................................................. 18  
Appendix A – Health claims on muscle function and physical performance evaluated by the EFSA NDA Panel... 19
Background and Terms of Reference as provided by EFSA

Background

Regulation (EC) No 1924/2006\(^1\) harmonises the provisions related to nutrition and health claims and establishes rules governing the Community authorisation of health claims made on foods. According to the Regulation, health claims should only be authorised for use in the Community after a scientific assessment of the highest possible standard to be carried out by EFSA.

Owing to the scientific and technical complexity of health claims, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)\(^2\) has placed considerable effort into developing scientific criteria for the substantiation of health claims, and has published guidance on the scientific substantiation of health claims since 2007.\(^3\)

Over the last number of years, the NDA Panel has gained considerable experience in the evaluation of health claim applications. To further assist applicants seeking approval of health claims, EFSA launched in 2014 a grant (GP/EFSA/NUTRI/2014/01) which aimed at gathering information in relation to claimed effects, outcome variables and methods of measurement in the context of the scientific substantiation of health claims. The information collected\(^4\) was to help inform the NDA Panel and serve as a basis for further guidance to applicants.

In this context, note is taken of the need to adapt the existing guidance on the scientific requirements for health claims\(^5\) to the new scientific and technical developments in specific areas, taking into account lessons learned from the evaluation of health claim applications and the information collected from the grant.

To this end, the NDA Panel is asked to update the existing guidance on the scientific requirements for health claims related to physical performance published in 2012.\(^6\)

Terms of Reference

The NDA Panel is requested by EFSA to update the existing guidance on the scientific requirements for health claims related to physical performance.

The guidance document shall clarify and address the scientific and technical developments in this area, taking into account the experience gained by the NDA Panel with the evaluation of health claims and the information collected from the grant.

The draft guidance shall be released for public consultation prior to finalisation, and shall be revised taking into account the comments received during the public consultation before adoption by the NDA Panel. A technical report on the outcome of the public consultation shall be published.

1. Introduction

The Guidance on the scientific requirements for health claims related to physical performance published in 2012 (EFSA NDA Panel, 2012c) laid down recommendations on specific issues that need to be addressed in applications submitted for the substantiation of health claims in this area. Since then, the Panel has evaluated additional health claim applications related to muscle function and physical performance.

Among the health claim applications submitted to EFSA as of 8/2/2018 (n = 490), 12 were relevant to this guidance: five were withdrawn during the evaluation, and seven were evaluated/finalised by the Panel. Among those finalised, three were evaluated by the Panel with a favourable outcome and all three referred to claims other than those based on the essentiality on nutrients: two were on muscle function and one on physical performance (Appendix A).

Examples of health claims evaluated by the Panel with a favourable outcome (under Article 13(1) and applications under Article 13(5)) will be used to provide guidance to applicants on the scientific requirements for the substantiation of health claims in these areas, whereas examples of claims evaluated by the NDA Panel with an unfavourable opinion will be used to illustrate the shortcomings that prevented the substantiation of these claims.

\(^{1}\) Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.

\(^{2}\) As from 1 July 2018, the NDA Panel has been renamed as EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA).

\(^{3}\) https://www.efsa.europa.eu/en/applications/nutrition/regulationsandguidance

\(^{4}\) https://www.efsa.europa.eu/en/supporting/pub/1277e

\(^{5}\) https://www.efsa.europa.eu/en/efsajournal/pub/2817
The information collected from the grant (GP/EFSA/NUTRI/2014/01) launched by EFSA in 2014, which aimed at gathering information in relation to claimed effects, outcome variables and methods of measurement in the context of the scientific substantiation of health claims, was considered by the Panel for updating this guidance.

2. Objectives and scope

This guidance is intended to assist applicants in preparing applications for the scientific substantiation of health claims related to muscle function and physical performance. The document focuses on:

- examples of claimed effects which are considered to be beneficial physiological effects;
- definition of the target population for which the claim is intended;
- characteristics of human intervention studies which can provide evidence for the scientific substantiation of specific claims addressed in this guidance (e.g. appropriate outcome variables and methods of measurement, suitable study group(s), suitable controls).

Issues related to scientific substantiation that are common to all health claims (e.g. principles applied for claims based on the essentiality of nutrients vs. claims other than those based on the essentiality of nutrients, aspects related to the characterisation of the food/constituent and to the characterisation of the claimed effect, examples of the evidence required for the substantiation of claims, criteria for the identification of pertinent human studies, extrapolation of the results from the study group to the target population) are addressed in the General scientific guidance for stakeholders on health claims applications (EFSA NDA Panel, 2016a) and will not be reiterated in this document.

This document has been developed based on previously published scientific opinions of the NDA Panel on health claims related to muscle function and physical performance. Thus, it represents the views of the NDA Panel based on the experience gained from the evaluation of health claims in these areas.

It is not intended that the document should:

- a) include an exhaustive list of beneficial effects and studies/outcome variables which are acceptable for claims substantiation, or
- b) address potential health relationships and related outcome variables/methods of measurement which have not been considered by the Panel yet in the context of a particular application.

This is because defining the conditions under which health relationships and outcome variables/methods of measurement for claimed effects may be acceptable is possible only in the context of specific applications, which are often unique and technically complex. For example, health relationships and outcome variables which may be acceptable in the context of a particular application may not be so in the context of another application with, for example, a different target population. The guidance rather presents examples drawn from evaluations already carried out to illustrate the approach of the Panel. This guidance will be kept under review and will be amended and updated in the light of experiences gained from the evaluation of additional health claim applications in this area.

This guidance should be read in conjunction with the General scientific guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016a), the Scientific and technical guidance for the preparation and presentation of a health claim application (EFSA NDA Panel, 2017), Regulation (EC) No 1924/2006 on nutrition and health claims made on foods, the Guidance on the implementation of Regulation (EC) No 1924/2006 (Standing Committee on the Food Chain and Animal Health, 2007), Commission Regulation (EC) No 353/2008, the Commission Implementing Decision of 24 January 2013 and future guidelines and regulations, as applicable.

---

6 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2006R1924:20100302:en:PDF
7 Commission Regulation (EC) No 353/2008 of 18 April 2008 establishing implementing rules for applications for authorisation of health claims as provided for in Article 15 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council (Text with EEA relevance) (OJ L 109, 19.4.2008, p. 11): http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2008R0353:20091221:EN:PDF
8 Commission Implementing Decision of 24 January 2013 adopting guidelines for the implementation of specific conditions for health claims laid down in Article 10 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council. OJ L 22, 25.1.2013, p. 25–28. Available at http://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32013D006
3. Definition of terms

During the scientific evaluation of health claims in the area of physical performance over the last 10 years, and in preparation for the update of this guidance document, the Panel has noticed the lack of consensus with respect to the terminology used in sport science (and practice) to describe different types of 'physical activities' or 'exercises' with respect to:

- their duration, 'intensity' and the effort required to perform them, and
- the methods and units of measurement of such effort.

Whereas a number of publications have proposed ways to standardise both nomenclature and 'exercise' classification depending on the type, 'intensity', duration and predominant metabolic pathways contributing to energy supply, they contradict each other in several ways (Caspersen et al., 1985; Howley, 2001; Chodzko-Zajko et al., 2009; Norton et al., 2010; Garber et al., 2011; Fisher and Smith, 2012; Chamari and Padulo, 2015; Winter et al., 2016).

Several terms for which there is no consensual definition have been used by the Panel in the context of specific health claim evaluations. Some of these terms (e.g. endurance capacity, strenuous exercise, short-term high-intensity exercise) have rather been defined for the purpose of the specific assessment (e.g. to establish conditions of use for the claim). Some other terms (e.g. muscle fatigue) had not been defined, assuming that they had a precise meaning and were well understood in the research field.

For the purpose of this guidance, and within the context of the scientific evaluation of health claims in the area of muscle function and physical performance, the Panel provides a common definition of terms to help communication between applicants, EFSA and risk managers. The Panel also indicates the information that should be provided in future applications to characterise the claimed effect, the target population and the conditions of use for the claim whenever common terms used in the scientific literature may lead to misinterpretation.

For the purpose of this guidance, and having regard of the scientific references cited above:

**Physical activity** is defined as any bodily movement produced by skeletal muscles, which requires energy expenditure. Physical activity broadly encompasses physical exercise, sports and physical activities done as part of daily living, occupation, leisure and active transportation.

**Physical fitness** is a set of attributes that people have or achieve that relates to the ability to perform physical activity (e.g. cardiorespiratory endurance, muscular endurance, muscular strength, body composition, flexibility, agility, balance, coordination, speed, power, reaction time). The degree to which people have these attributes can be measured with specific tests.

**Physical exercise** is defined as a subset of physical activity that is planned and structured, and has as a final or an intermediate objective the improvement or maintenance of one or more components of physical fitness.

**Resistance exercise (training)** is a specific type of physical exercise designed to increase muscular strength, power and/or endurance. It can vary in the resistance, speed, the number of times the resistance is moved in a single group (set) of exercise, the number of sets done and the rest interval provided between sets.

*Intensity/load, frequency, duration and mode/type* are used to describe the characteristics of an exercise to bring about a particular response. Their combination affects the volume of the exercise and the predominant metabolic pathways and substrates that are involved.

**Intensity/load** refers to the effort required by an individual to complete a given physical activity or exercise. Objective measures of exercise intensity are usually expressed as relative values (e.g. %HR_max, %HRR, %VO_2max, %VO_2R). Exercise intensity has also been classified using subjective measures, i.e. relative to the subject's perception of effort, using the Borg's Rating of Perceived Exertion (RPE) scale. For resistance training, 'intensity' refers to the amount of resistance (load). The one repetition maximum (1RM), which is the greatest weight that can be lifted or displaced one time in good form, is relevant for dynamic measurements, whereas the maximal voluntary contraction (MVC) is relevant for isometric measurements. Objective measures of load are usually expressed as relative values (e.g. %1RM, %MVC).

---

9 HRR = HR_max – resting HR
10 VO_2R = VO_2max – resting VO_2
**Frequency** in training programmes is described as the number of activity sessions per day, week or month.

**Duration** refers to the number of minutes of activity in each exercise session (and to the duration of each interval within a session for interval training).

**The mode/type** refers to the type of exercise performed (e.g. cycling, running, swimming, weight-lifting, etc.) and to whether this is intermittent (e.g. repeated bouts, sprints, interval training) or continuous.

Whereas several classifications of physical exercise have been proposed with respect to their intensity and duration, the main metabolic pathways involved and/or the type of physical fitness targeted, the Panel notes that the nomenclature in this field is not harmonised. Therefore, in the context of claims substantiation, the claimed effect (e.g. the testing conditions under which the food/constituent may affect performance) must be described (characterised) in terms of mode/type of exercise, intensity/load (using objective measures and expressed as relative values) and duration (in minutes). The characterisation of training programmes which may be part of the conditions of use for the claim (e.g. if the efficacy of food/constituent on performance is only observed when its consumption is coupled to a training program) requires also information on frequency. The characterisation of physical exercises for the substantiation of health claims on physical performance and physical capacity is addressed in Section 4.2.2.

**Muscle contraction** is the activation of tension-generating sites within muscle fibres and can be concentric or eccentric.

**Muscle strength** refers to the (maximum) amount of external force that a skeletal muscle (or muscle group) can exert. It may be expressed as MVC for isometric measurements and as the 1RM for dynamic measurements.

**Endurance** is the ability to sustain a physical activity or exercise over a period of time.

**Muscle endurance** refers to the ability of muscle groups to exert and maintain an external force for a number of repetitions or successive exertions against a constant resistance.

**Muscle fatigue** is defined as any exercise-induced reduction in the maximal capacity to generate force or power output, or in the capacity to maintain a predefined force or power output.

Exercise-induced **muscle soreness** is an aching sensation following muscular exertion that can be acute (i.e. the immediate ache perceived by the athlete while or immediately after exercise) or delayed. Delayed-onset muscle soreness (DOMS) generally occurs following unaccustomed muscular exertion and is mainly related to eccentric muscular efforts. Muscle soreness can vary from mild discomfort to incapacitating pain depending on the intensity, volume and novelty of the exercise.

Exercise-induced **muscle damage** refers to the disruption of muscle fibres during exercise which may be associated to a reduction of muscle function. Muscle damage may lead to pain and soreness, but these may also occur in the absence of muscle damage.

**Mechanical work** is the amount of energy transferred by a force acting over a certain distance.

**Power** relates to the rate at which mechanical work can be performed.

**Physical performance** is the ability to complete certain physical tasks. An increase in physical performance refers to completion of a given physical task with higher intensity, and therefore faster or with a higher power output.

**Physical capacity** is the ability to continue a physical activity despite increasing physical or psychological stress, and refers to the exercise time to fatigue when exercising at predefined conditions (e.g. a given load, intensity or speed).

Appropriate outcome variables to assess physical capacity and physical performance in human intervention studies are discussed in Section 4.2.2.

The terms **endurance capacity and endurance performance** have been used by the Panel in previous guidance documents and scientific opinions to denote physical capacity and performance assessed during physical exercises of ‘moderate’ intensity (generally < 80% VO₂max). These terms will

---

11 For example: endurance, cardiorespiratory, flexibility, and neuromuscular exercise; ‘aerobic’ and ‘anaerobic’ exercise; sedentary, light, moderate, vigorous and high-intensity exercise; all-out (maximal) efforts: ‘explosive’, ‘high intensity’, ‘endurance intensive efforts’. 
only be used in the present guidance to describe examples of previous evaluations for illustration purposes.

The target population for the claim should be characterised in terms of age and level of physical fitness (or level of training) if: (a) these characteristics are thought to affect the relationship between the intake of the food/constituent and the claimed effect, and/or (b) if the studies provided for the substantiation of the claim have been conducted in specific study groups (e.g. elderly male subjects) and the extrapolation of the results to the general (healthy) population cannot be justified.

The Panel notes, however, that there is no consensus on the definition of terms such as ‘moderately active individuals’, ‘recreationally active individuals’, ‘athletes’ or ‘elite athletes’. Similarly, common terms used to define age groups (e.g. adolescents, elderly subjects) may correspond to different age ranges. Therefore, for the purpose of characterising the target population in the area of health claims related to muscle function and physical performance, age and/or level of physical fitness (or training) should be indicated as precisely as possible whenever these characteristics are important to establish conditions of use for the claim. For example, the level of physical fitness (or level of training) of the target population would be better described by characteristics such as the intensity/load, frequency, duration, and mode/type of the physical exercise being performed on regular basis, while years (or age ranges) would be more appropriate to describe age.

4. **Assessment**

4.1. **Function claims based on the essentiality of nutrients**

Several health claims related to essential nutrients have been scientifically substantiated based on the principle of the essentiality of these nutrients\(^\text{12}\): (i) the nutrient is required for normal human body function(s), i.e. it has an essential mechanistic role in a metabolic function and/or it has the ability to reverse clinical signs and symptoms of its deficiency; (ii) the nutrient cannot be synthesised by the body or cannot be synthesised in amounts which are adequate to maintain normal body function(s) and (iii) the nutrient must be obtained from a dietary source. For these claims (described below in this sections), the Panel did not review the primary scientific studies submitted and it did not weigh the evidence.

4.1.1. **Claims on muscle function**

The improvement, maintenance or reduced loss of muscle function (contraction) is considered a beneficial physiological effect. Failure to increase muscle mass during growth and development, and the loss of muscle mass at any age, will impair muscle function (e.g. muscle strength and power). Faster recovery of normal muscle function after exercise is also considered a beneficial physiological effect.

Claims on the well-established role of some minerals such as sodium (EFSA NDA Panel, 2011g), potassium (EFSA NDA Panel, 2010h), magnesium (EFSA NDA Panel, 2009c) and calcium (EFSA NDA Panel, 2009a) on the maintenance of normal muscle function (contraction) have been evaluated by the Panel with a favourable outcome. The target population for these claims was the general healthy population. Conditions of use were established on the basis that any significant amount of the essential nutrient in the diet will contribute to the claimed effect (i.e. conditions of use were linked to nutrition claims).

A claim on dietary protein and growth or maintenance of muscle mass was also evaluated by the Panel with a favourable outcome (EFSA NDA Panel, 2010a). The Panel considered that the role of dietary protein in the growth (during development) and maintenance (after adolescence) of whole body lean body mass, including muscle mass, was well-established. Maintenance of lean body mass can be achieved if (protein) nitrogen intake is equal to or above (protein) nitrogen losses over a period of time. It is well documented that protein intake is necessary to maintain nitrogen (protein) balance as nitrogen is lost from the body primarily via the urine, but also in small amounts via faeces, sweat, skin, hair and nails. Similarly, maintenance of muscle mass is typically achieved if mean muscle protein synthesis rate is equal to mean muscle protein breakdown rate over a period of time. Protein intakes within the Dietary Reference Values (DRVs) allow for the growth and maintenance of lean body mass, including muscle mass, for normal protein turnover, and for muscle recovery after physical exercise. The target population for this claim was the general healthy population. Conditions of use were

\(^{12}\) See General scientific guidance for stakeholders on health claim applications, Section 6.1.
established on the basis that any significant amount of protein in the diet will contribute to the claimed effect (i.e. conditions of use were linked to nutrition claims).

For the scientific substantiation of health claims related to specific protein sources or protein components on measures of muscle function (i.e. muscle mass and muscle strength), see Section 4.2.1.

4.2. Function claims other than those based on the essentiality of nutrients

4.2.1. Claims on muscle function

Function claims other than those based on the essentiality of nutrients have been submitted on muscle strength, rather than on muscle function. Noting that muscle strength is a specific aspect of muscle function, claims may refer to muscle strength specifically, rather than to muscle function in general. In this context, outcome variables that are appropriate to assess muscle strength in human studies include 1RM and isometric strength tests (e.g. 1RM weight lifting (bench press), 1RM leg press, 1RM knee extension, 1RM biceps curl, isometric handgrip strength, isokinetic knee extension torque). Owing to these single outcome variables of muscle strength generally assessing specific muscle groups, the evaluation of general muscle strength requires the use of multiple outcome variables in combination (e.g. assessing muscle strength in the upper and lower body). Outcome variables related to motor functional performance (e.g. gait speed, timed-get-up-and-go test, stair climbing) are not direct measures of muscle strength. The use of these outcome variables in the scientific substantiation of claims on physical performance is discussed in Section 4.2.2.1.

Outcome variables related to body composition (e.g. whole-body lean body mass, muscle mass) or muscle structure (e.g. muscle shape, number and type of muscle fibres, muscle damage, muscle tissue repair) are not direct measures of muscle function. However, since changes in one or more of these outcome variables may contribute to the improvement, maintenance or reduced loss of muscle function, they could be used as supportive evidence for the scientific substantiation of claims on muscle function/strength. Invasive (e.g. muscle biopsy) and non-invasive (e.g. high-frequency ultrasound, magnetic resonance imaging) techniques can be used to assess different components of muscle structure. Claims related to changes in body composition have been addressed in the 'Guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations' (EFSA NDA Panel, 2012d). Measures of muscle protein turnover (rates of muscle protein synthesis and breakdown) could be used in support of a mechanism by which the food/constituent could lead to an increase in muscle mass and/or muscle strength.

The scientific evaluation of health claims on muscle strength requires sufficient characterisation of the target population for which the claim is made and of the conditions of use for the claim. The target population for the claim should be sufficiently characterised regarding physical fitness and/or age of the subjects, whenever these characteristics are thought to affect the relationship between the intake of the food/constituent and the claimed effect. The conditions of use for the claim should clearly indicate all aspects related to:

a) the consumption of the food constituent (e.g. the amount, the frequency of consumption, the timing of consumption in relation to the physical exercise), and

b) the concomitant intervention(s) that are important/needed to achieve the claimed effect, as appropriate (e.g. type/intensity/frequency/duration of concomitant training).

A claim on creatine in combination with resistance training and improvement in muscle strength was evaluated by the Panel with a favourable outcome (EFSA NDA Panel, 2016b). The target population for the claim was adults > 55 years of age who are engaged in regular resistance training. The scientific assessment was based on the results of 10 human intervention studies provided by the applicant and on evidence for a mechanism by which creatine could exert the claimed effect. The human intervention studies investigated multiple outcome variables of muscle strength (e.g. 1RM weight lifting (bench press), 1RM chest press, 1RM knee extension, 1RM biceps curl, 1RM leg press and 1RM leg extension) in different combinations in order to assess upper and lower body muscle strength using different protocols. Overall, the human intervention studies submitted provided evidence for an effect of creatine consumed at doses of at least 3 g/day in combination with regular resistance training (three times per week for several weeks) of moderate intensity on muscle strength in adults 55 years of age and older. No such effect was observed when similar weekly doses of...
The recovery or restoration of muscle function (e.g. muscle strength, contraction) after exercise is considered a beneficial physiological effect. Human intervention studies investigating the effect of a food/constituent consumed before (either acutely or chronically), during and/or after an initial strenuous exercise bout on performance parameters at a subsequent exercise bout after a recovery period are appropriate to assess these claims (e.g. repetitions-to-fatigue test re-test). Subjective measures of (perceived) muscle fatigue/exertion or muscle soreness (e.g. validated questionnaires) may be used as supportive evidence in this context. Measures of skeletal muscle glycogen stores, measures of muscle protein turnover (rates of muscle protein synthesis and breakdown) and some measures of muscle structure (e.g. muscle damage, muscle tissue repair) can provide support for a mechanism by which the food/constituent could exert the claimed effect. A health claim related to glycaemic carbohydrates and faster recovery of normal muscle function (contraction) after strenuous exercise was evaluated by the Panel with a favourable outcome (EFSA NDA Panel, 2013). The scientific substantiation of this claim relied on consensus opinions from authoritative bodies, which were based on a wealth of human intervention (efficacy) studies, human studies on methods used for measuring muscle glycogen stores, and mechanistic in vitro and animal studies. The Panel also considered that the mode of action was well established. The target population for this claim was individuals performing strenuous exercise. The conditions of use for this claim were rather based on the amount of carbohydrates and consumption time relative to the exercise which could increase glycogen re-synthesis in muscle and restore skeletal muscle glycogen stores.

A number of claims related to specific protein sources (e.g. bovine colostrum, casein protein hydrolysates, whey protein), specific amino acids which are incorporated into proteins (e.g. BCAA, L-glutamine) or specific constituents derived from protein amino acids (L-carnitine, L-carnosine) have been evaluated by the Panel with an unfavourable opinion (Appendix A). The claimed effects were growth or maintenance of muscle mass, maintenance of normal muscle function, faster recovery of muscle function/strength/glycogen stores after exercise, faster recovery from muscle fatigue after exercise and skeletal muscle tissue repair.

For the scientific substantiation of claims on the effects of specific protein sources/constituents on outcome variables related to muscle mass and muscle function (e.g. muscle strength), human intervention studies assessing the effect of a specific protein source/constituent against another isonitrogenous protein source/constituent were considered as pertinent to the claim, whereas studies controlling for energy only (e.g. using isocaloric carbohydrate sources as comparator) could not be used for the scientific substantiation of these claims. Measures of whole body lean mass in combination with measures of muscle strength were considered appropriate to assess changes in muscle mass. For well-characterised protein sources/constituents, the Panel concluded that a cause and effect relationship had not been established between the consumption of specific protein sources/constituents and growth or maintenance of muscle mass over and above the well-established role of protein on the claimed effect (i.e. beyond what could be expected from the consumption of mixed dietary protein within the DRV when energy and other nutrient requirements are met; (EFSA NDA Panel, 2012a); see also Section 4.1.1).

Two applications on citrulline malate and faster recovery from muscle fatigue after exercise were evaluated by the Panel with an unfavourable opinion (EFSA NDA Panel, 2012b, 2014a). The human intervention studies provided for the scientific substantiation of the claim assessed subjective measures of muscle soreness after strenuous exercise, blood lactate concentrations during exercise and/or perceived fatigue during exercise. Performance parameters were not assessed in those studies. The Panel considered that, while there is consensus on the contribution of training in reducing blood lactate concentrations during and after exercise and on delaying muscle fatigue during exercise, no evidence was provided that lowering blood lactate through a dietary intervention can prevent or alleviate loss of muscle function during exercise or can lead to a faster recovery from muscle fatigue by contributing to the restoration of muscle function after exercise. The Panel also noted that there is no consensus on the role of lactate in the recovery from muscle fatigue.

---

13 See the General scientific guidance EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016a. General scientific guidance for stakeholders on health claim applications EFSA Journal 2016;14(1):4367, 38 pp. https://doi.org/10.2903/j.efsa.2016.4367, i.e. Annex C—Considerations on the validation of questionnaires and their use as outcome variables for the scientific substantiation of health claims.
4.2.2. Claims on physical performance and physical capacity

Physical performance is the ability to complete certain physical tasks. An increase in physical performance refers to completion of a given physical task with higher intensity, and therefore faster or with a higher power output. Measures of physical performance are obtained in the context of task-limited (e.g. time spent to run/row/swim or cycle a predefined distance) or time-limited (e.g. maximum distance cycled in a predefined time) physical activities. Improvement, maintenance or reduced loss of physical performance is a beneficial physiological effect for individuals performing physical exercise for different reasons (e.g. athletes preparing for a competition or during a competition, individuals engaged in recreational activities), but also for individuals performing common (non-exercise related) physical tasks.

Physical capacity, on the other hand, refers to the exercise time to fatigue when exercising at predefined conditions (e.g. a given workload, intensity or speed). Exercise time to fatigue is an appropriate measure of physical capacity. An increased physical capacity is a beneficial physiological effect for individuals performing physical exercise which is not limited by time or task (e.g. recreational running, walking, swimming, cycling and fitness training).

Although an increase in physical capacity (e.g. the time that an individual can exercise to fatigue at a given workload, intensity or speed) may lead to an improvement in physical performance, measures of physical capacity are not appropriate outcome variables for the scientific substantiation of claims on physical performance and vice versa. An increase in physical capacity, however, could be associated to an increase in physical performance and therefore measures of physical capacity could be used to support an effect of the food/constituent on physical performance.

Claims on specific physiological effects (e.g. reduction in rated perceived exertion/effort during exercise, enhancement of water absorption during exercise) which may lead to an improvement in physical capacity and/or performance have been proposed and evaluated by the Panel. A claim related to carbohydrate-electrolyte solutions and enhancement of water absorption during exercise (EFSA NDA Panel, 2011h), and a claim related to caffeine (EFSA NDA Panel, 2011j) and the reduction in the rated perceived exertion/effort during exercise, have been evaluated by the Panel with a favourable outcome. For both food/constituents, a claim on increase/maintenance of endurance performance (carbohydrate-electrolyte solutions and caffeine) and/or a claim on increased endurance capacity (caffeine) were also evaluated by the Panel with a favourable outcome within the same scientific opinion (Appendix A). The Panel considers that specific physiological effects such as the reduction in the rated perceived exertion/effort during exercise or an enhancement of water absorption during exercise could be the mechanisms by which a food/constituent could exert an effect on physical capacity or performance. However, evidence that the food/constituent has an effect on direct measures of physical capacity or physical performance should also be provided.

4.2.2.1. Claims on physical performance

The scientific evaluation of health claims on physical performance requires sufficient characterisation of the exercise or physical activity under evaluation, of the target population for which the claim is made, and of the conditions of use for the claim. These aspects may be tightly linked to knowledge (or hypotheses) on the mechanisms by which the food/constituent could exert the claimed effect.

The exercise or physical activity under evaluation (e.g. the testing conditions under which the food/constituent may affect performance) needs to be characterised by:

a) the mode/type of exercise or physical activity. The type of exercise (e.g. cycling, running, swimming, weight-lifting) or physical activity (e.g. walking), and whether it is intermittent (e.g. repeated bouts, sprints, repetitions maximum) or continuous (e.g. running at constant speed, cycling at a given cadence) needs to be indicated;

b) the intensity/load expressed in relative terms using objective measures (e.g. %HR_max, %HRR, %VO2max, %VO2R; %1RM, %MVC);

c) duration, as minutes of activity in each exercise session. For intermittent exercises, the number and duration of exercise sets/intervals, and the number and duration of rest periods within a session, should also be indicated.

Owing to the vast variety of exercise protocols that are being used to test physical performance in humans, additional information may be required for their characterisation. For example, test trials (e.g. a time-limited, self-paced maximal cycling ride) may be preceded by other trials of fixed intensity and
duration to increase harmonisation of the pretest conditions (EFSA NDA Panel, 2018). If that is the case, the pretest physical exercise should also be described in terms of mode/type, intensity and duration as accurately as possible. Duration and intensity of the exercise should be expressed quantitatively (e.g. duration in minutes, intensity as %VO_{2\text{max}}) rather than qualitatively (e.g. short duration, high intensity).

The target population for the claim should be sufficiently characterised regarding fitness status and/or age whenever these characteristics are thought to affect the relationship between the intake of the food/constituent and the claimed effect.

Outcome variables/methods of measurement of physical performance which may be appropriate for the assessment of the claimed effect in humans in the context of a particular type of exercise or physical activity should be indicated (e.g. time spent to run a certain distance, distance cycled during a time trial).

As for the conditions of use, when the food/constituent should be consumed relative to the physical performance test (e.g. before and/or during exercise), the duration of the intervention, and the need of concomitant training, are important aspects to consider. In this context, training programs should also be characterised in relation to the mode/type (e.g. resistance training; swimming), the intensity/load (where appropriate), the duration of each session and the frequency (e.g. number of activity sessions per day, week, or month).

Cycling, running, swimming or rowing time-trial tests (e.g. a sort of race where individuals try to cover a predefined distance as fast as possible) are task-limited physical activities that can be used to assess physical performance both in the general population and in athletes practising such sports. The time spent to cover a certain distance, either alone or in combination with the total/mean work/power output developed during the time-trial test, is an appropriate outcome measure of physical performance. The time spent to cover a certain distance depends on individual conditional capacities, like resistance, speed, muscular power and strength, which can be modified (improved) by training. Jumping height is critical for a successful performance in many sport activities, like basketball or volleyball, and can be used as a measure of physical performance in the general population. Throwing distance in javelin throw or shot put are also appropriate task-limited measures of physical performance. However, since these are highly technical field disciplines, the use of these outcomes is limited to the evaluation of physical performance in javelin throwers or shot putter athletes. Conversely, task (distance/work)-limited walking speed tests are appropriate for the substantiation of health claims on reduced loss of physical performance in the elderly, whereas their use to assess changes in physical performance in other population subgroups (e.g. physically competent children and adults, athletes) is limited.

Physical performance can also be assessed in the context of time-limited physical activities as the maximal distance covered by, e.g. cycling, running, swimming or rowing within a predefined time, either alone or in combination with the total/mean work/power output developed during the test.

The use of other task-limited or time-limited tests of physical performance, such as walking speed or the number of chair-stands in a certain time, are more appropriate for the substantiation of health claims on the improvement (i.e. reduced loss) of physical performance in the elderly.

Some of the outcome variables proposed for the substantiation of claims on physical performance (e.g. changes in VO_{2\text{max}}, increase muscle glycogen stores, changes in substrate oxidation, blood lactate concentrations, muscle carnosine stores) are not direct measures of performance, but could be used in support of a mechanism by which the food/constituent could exert the claimed effect. A claim on creatine and increase in physical performance during short-term, high intensity, repeated exercise bouts has been evaluated by the Panel with a positive outcome (EFSA NDA Panel, 2011k). The scientific substantiation of the claim was based on a wealth of human intervention studies which investigated the effects of different creatine doses, patterns of consumption and duration of the supplementation on physical performance during continuous and intermittent physical activities of variable intensity and duration in various population subgroups (men and women of different ages and levels of training); on the results of two meta-analysis summarising the results of the above-mentioned human studies; and on the well-established mechanism by which creatine could exert the claimed effect. The conditions of use for the claim were established based on the results of the human intervention studies (i.e. minimum effective daily dose). The target population was adults performing high-intensity exercise. Conversely, the human studies provided did not show an effect of creatine supplementation on measures of endurance capacity or endurance performance, and there was no consensus on the role of creatine in increasing endurance capacity or endurance performance.
A claim on β-alanine and increase in physical performance during short-duration, high intensity exercise has been evaluated by the Panel with an unfavourable outcome (EFSA NDA Panel, 2014b). Human intervention studies on the effects of β-alanine on measures of physical capacity (e.g. time to exhaustion and/or total work done and/or physical working capacity at fatigue threshold) in the context of time unlimited physical activities which did not report on any measures of physical performance were excluded from the assessment. The main outcomes investigated in the remaining studies were the time spent to complete a certain task (run, row, swim or cycle a predefined distance) and power output in time-limited (all-out or maximal effort) tasks lasting seconds. Overall, no effect of β-alanine supplementation on measures of physical performance was found.

A claim on carbohydrate solutions and increase in physical performance during a high-intensity and long-lasting physical exercise has been evaluated by the Panel with a favourable outcome (EFSA NDA Panel, 2018). The applicant defined high-intensity and long-lasting physical exercises as those being performed at least at 65% of the VO\textsubscript{2max} at maximal effort, or during a time-trial test for at least 60 min. The scientific substantiation of the claim was based on the results of four human intervention studies conducted in non-fasting conditions after a standard meal, which were supported by the results of four intervention studies conducted after an overnight fast and the results of two intervention studies conducted under poorly specified nutritional conditions (e.g. at least a 4-h fast). In these studies, trained participants underwent one or more exercise trials of fixed intensity (generally ≥65% of the VO\textsubscript{2max} or 70–80% of HR\textsubscript{max}) and duration (overall lasting > 60 min), followed by an all-out test in which performance was measured. Different types of exercise (e.g. cycling, running) were used for the pretest and the test trials, which were either continuous, intermittent, or a combination of these (e.g. a cycling trial before and during the test; four cycling trials of eight intermittent bouts followed by an all-out maximal ride). Carbohydrate solutions (containing glucose, mixtures of glucose and fructose, sucrose and/or maltodextrins) were consumed before and/or during the exercise session. The target population for the claim was defined as healthy trained adults performing high-intensity (at least 65% of the VO\textsubscript{2max}) and long-lasting (at least 60 min) physical exercise.

A claim on caffeine and an increase in endurance performance has been evaluated by the Panel with a positive outcome (EFSA NDA Panel, 2011j). The Panel took into account that most of the human intervention studies provided using no time-limited exercise protocols (including a meta-analysis of 23 RCTs evaluating 39 outcomes and two individual RCTs) showed an effect of caffeine consumption on endurance performance at doses of at least 3 mg/kg body weight administered at least 1 h prior to exercise, and after at least 1 day of caffeine withdrawal, in habitual caffeine consumers.

4.2.2.2. Claims on physical capacity

The scientific evaluation of health claims on physical capacity requires sufficient characterisation of the claimed effect and of the target population for which the claim is made.

Physical capacity can be assessed in human intervention studies using several exercise protocols as long as they are not task- or time-limited overall, so that subjects can exercise to fatigue. The particular mode/type of exercise (e.g. cycling, running and swimming; single bout vs repeated bouts) and the conditions in which physical capacity is tested (e.g. intensity of the exercise, speed, power output) should be specified. The exercise time to fatigue under defined conditions can be assessed by using objective (e.g. cycling cadence, running speed) or self-reported (e.g. with a validated questionnaire) measurements of physical fatigue. As for claims on physical performance, the target population for the claim should be sufficiently characterised regarding fitness status and/or age. The amount and the time of consumption of the food/constituent relative to the exercise test (e.g. before and/or during exercise) is an important aspect to consider when establishing conditions of use.

A claim on caffeine and an increase in endurance capacity has been evaluated by the Panel with a favourable outcome (EFSA NDA Panel, 2011j). The Panel took into account that most of the human intervention studies provided using no time-limited exercise protocols (including a meta-analysis of 23 RCTs evaluating 39 outcomes and two individual RCTs) showed an effect of caffeine consumption on endurance performance at doses of at least 3 mg/kg body weight administered at least one hour prior to exercise, and after at least 12 h of caffeine withdrawal, in habitual caffeine consumers. The Panel also considered that a plausible mechanism by which caffeine could exert the claimed effect is through the reduction of perceived exertion during exercise, a claim which was evaluated in the same scientific opinion with a positive outcome.
References
Caspersen CJ, Powell KE and Christenson GM, 1985. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Reports, 100, 126–131.
Chamari K and Padulo J, 2015. ‘Aerobic’ and ‘Anaerobic’ terms used in exercise physiology: a critical terminology reflection. Sports Medicine - Open, 1, 9.
Chodzko-Zajko WJ, Proctor DN, Flattarone Singh MA, Minson CT, Nigg CR, Salem GJ and Skinner JS, 2009. American College of Sports Medicine position stand. Exercise and physical activity for older adults. Medicine and Science in Sports and Exercise, 41, 1510–1530.
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2009a. Scientifc Opinion on the substantiation of health claims related to calcium and growth, development and maintenance of the normal structure and function of bones and teeth (ID 224, 230, 231, 354, 3099), muscle function and neurotransmission (ID 226, 227, 230, 235), blood coagulation (ID 230, 236), energy-yielding metabolism (ID 234), normal function of digestive enzymes (ID 355), and maintenance of a normal blood pressure (ID 225, 385, 1419) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2009;7(9):1210, 27 pp. https://doi.org/10.2903/j.efsa.2009.1210
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2009b. Scientifc Opinion on the substantiation of health claims related to magnesium and electrolyte balance (ID 238), energy-yielding metabolism (ID 240, 247, 248), neurotransmission and muscle contraction including heart muscle (ID 241, 242), cell division (ID 365), maintenance of bone (ID 239), maintenance of teeth (ID 239), blood coagulation (ID 357) and protein synthesis (ID 364) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2009;7(9):1260, 17 pp. https://doi.org/10.2903/j.efsa.2009.1260
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2009c. Scientifc Opinion on the substantiation of health claims related to taurine and protection of DNA, proteins and lipids from oxidative damage (ID 612, 1658, 1959), energy-yielding metabolism (ID 614), and delay in the onset of fatigue and enhancement of physical performance (ID 1660) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2009;7(9):1216, 20 pp. https://doi.org/10.2903/j.efsa.2009.1216
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010a. Scientifc Opinion on the substantiation of health claims related to protein and increase in satiety leading to a reduction in energy intake (ID 414, 616, 730), contribution to the maintenance or achievement of a normal body weight (ID 414, 616, 730), maintenance of normal bone (ID 416) and growth or maintenance of muscle mass (ID 415, 417, 593, 594, 595, 715) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1811, 24 pp. https://doi.org/10.2903/j.efsa.2010.1811
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010b. Scientifc Opinion on the substantiation of health claims related to superoxide dismutase (SOD) and protection of DNA, proteins and lipids from oxidative damage (ID 1785, 1839, 1970, 2304, 2305, 3159, 3160), protection of the skin from photo-oxidative (UV-induced) damage (ID 2305, 3161), reduction of muscle fatigue during exercise (ID 1840), and "effects on immune system" (ID 2304, 3160) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1753, 20 pp. https://doi.org/10.2903/j.efsa.2010.1753
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010c. Scientifc Opinion on the substantiation of health claims related to whey protein and increase in satiety leading to a reduction in energy intake (ID 425), contribution to the maintenance or achievement of a normal body weight (ID 1683), growth and maintenance of muscle mass (ID 418, 419, 423, 426, 427, 432, 4307), increase in lean body mass during energy restriction and resistance training (ID 421), reduction of body fat mass during energy restriction and resistance training (ID 420, 421), increase in muscle strength (ID 422, 429), increase in endurance capacity during the subsequent exercise bout after strenuous exercise (ID 428), skeletal muscle tissue repair (ID 428) and faster recovery from muscle fatigue after exercise (ID 423, 428, 431), pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1818, 28 pp. https://doi.org/10.2903/j.efsa.2010.1818
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010d. Scientifc Opinion on the substantiation of health claims related to beta-alanine and increase in physical performance during short-term high-intensity exercise (ID 436, 1453, 1454, 1459), increase in time to exhaustion (ID 437, 438, 439, 683, 1452, 1455, 1456, 1459) and increase in muscle carnosine stores (ID 1457, 1458) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1729, 18 pp. https://doi.org/10.2903/j.efsa.2010.1729
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010e. Scientifc Opinion on the substantiation of health claims related to soy phosphatidyl choline and maintenance of normal blood cholesterol concentrations (ID 709, 1308, 1630, 1961, 3138, 3187, 4687), contribution to normal fat metabolism (ID 1597), increase in the intestinal absorption of glutamine (ID 4251), faster recovery from muscle fatigue after exercise (ID 4249), improvement of neuromuscular function (ID 4250), contribution to normal cognitive function (ID 710, 1596, 1631, 1983) and maintenance of normal neurological function (ID 1596) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1741, 26 pp. https://doi.org/10.2903/j.efsa.2010.1741
Guidance for health claims on muscle function and physical performance

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010f. Scientific Opinion on the substantiation of health claims related to coenzyme Q10 and contribution to normal energy-yielding metabolism (ID 1508, 1512, 1720, 1912, 4668), maintenance of normal blood pressure (ID 1509, 1721, 1911), protection of DNA, proteins and lipids from oxidative damage (ID 1510), contribution to normal cognitive function (ID 1511), maintenance of normal blood cholesterol concentrations (ID 1721) and increase in endurance capacity and/or endurance performance (ID 1913) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1793, 27 pp. https://doi.org/10.2903/j.efsa.2010.1793

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010g. Scientific Opinion on the substantiation of health claims related to branched-chain amino acids (BCAA) and growth or maintenance of muscle mass (ID 442, 444, 445, 447, 448, 451, 1478), attenuation of the decline in muscle power following exercise at high altitude (ID 443), faster recovery from muscle fatigue after exercise (ID 447, 448, 684,1478), improvement of cognitive function after exercise (ID 446), reduction in perceived exertion during exercise (ID 450) and “healthy immune system” (ID 449) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1790, 24 pp. https://doi.org/10.2903/j.efsa.2010.1790

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010h. Scientific Opinion on the substantiation of health claims related to potassium and maintenance of normal muscular and neurological function (ID 320, 386) and maintenance of normal blood pressure (ID 321) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(2):1469, 17 pp. https://doi.org/10.2903/j.efsa.2010.1469

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011a. Scientific Opinion on the substantiation of health claims related to L-carnitine and faster recovery from muscle fatigue after exercise (ID 738, 1492, 1493), skeletal muscle tissue repair (ID 738, 1492, 1493), increase in endurance capacity (ID 4305, 4684), maintenance of normal blood LDL-cholesterol concentrations (ID 1494, 4684), contribution to normal spermatogenesis (ID 1822), “energy metabolism” (ID 1821), and increasing L-carnitine concentrations and/or decreasing free fatty acids in blood during pregnancy (ID 1495) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2212, 24 pp. https://doi.org/10.2903/j.efsa.2011.2212

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011b. Scientific Opinion on the substantiation of health claims related to L-carnosine and increase in muscle power (ID 1824), increase in endurance capacity (ID 1824), “skin” (ID 1825) and maintenance of normal cardiac function (ID 1826) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2038, 14 pp. https://doi.org/10.2903/j.efsa.2011.2038

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011c. Scientific Opinion on the substantiation of health claims related to L-glutamine and growth or maintenance of muscle mass (ID 719, 722, 3185), faster restoration of muscle glycogen stores after strenuous exercise (ID 434, 699, 701, 723, 1569), skeletal muscle tissue repair (ID 721), maintenance of normal neurological function (ID 662, 700), increased attention (ID 700, 1570), improvement of working memory (ID 700, 1570), maintenance of defence against pathogenic gastro-intestinal microorganisms (ID 452), gut protein synthesis (ID 701), decreasing gut permeability (ID 701), and stimulating immunological responses (ID 1568) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2225, 27 pp. https://doi.org/10.2903/j.efsa.2011.2225

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011d. Scientific Opinion on the substantiation of health claims related to ribose and faster recovery from muscle fatigue after exercise (ID 4226) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2257, 14 pp. https://doi.org/10.2903/j.efsa.2011.2257

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011e. Scientific Opinion on the substantiation of health claims related to taurine and ”immune system protection” (ID 611), ”metabolism processes” (ID 613), contribution to normal cognitive function (ID 1659), maintenance of normal cardiac function (ID 1661), maintenance of normal muscle function (ID 1949) and delay in the onset of physical fatigue during exercise (ID 1958) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2035, 19 pp. https://doi.org/10.2903/j.efsa.2011.2035

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011f. Scientific Opinion on the substantiation of health claims related to sodium phosphate and increase in endurance performance (ID 318, 386) and maintenance of normal muscular and neurological function (ID 321), contribution to normal energy-yielding metabolism (ID 320), “healthy immune system” (ID 321), and increasing L-carnitine concentrations and/or decreasing free fatty acids in blood during pregnancy (ID 321) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2263, 15 pp. https://doi.org/10.2903/j.efsa.2011.2263

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011g. Scientific Opinion on the substantiation of health claims related to sodium and maintenance of normal muscle function (ID 359) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2260, 14 pp. https://doi.org/10.2903/j.efsa.2011.2260

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011h. Scientific Opinion on the substantiation of health claims related to carbohydrate-electrolyte solutions and reduction in rated perceived exertion/effort during exercise (ID 460, 466, 467, 468), enhancement of water absorption during exercise (ID 314, 315, 316, 317, 319, 322, 325, 332, 408, 465, 473, 1168, 1574, 1593, 1618, 4302, 4309), and maintenance of endurance performance (ID 466, 469) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2211, 29 pp. https://doi.org/10.2903/j.efsa.2011.2211
Guidance for health claims on muscle function and physical performance

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011i. Scientific Opinion on the substantiation of health claims related to adenosine triphosphate (ATP) and maintenance of normal muscle function (ID 1494) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2081, 14 pp. https://doi.org/10.2903/j.efsa.2011.2081

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011. Scientific Opinion on the substantiation of health claims related to caffeine and increase in physical performance during short-term high-intensity exercise (ID 737, 1486, 1489), increase in endurance performance (ID 737, 1486), increase in endurance capacity (ID 1488) and reduction in the rated perceived exertion/effort during exercise (ID 1488, 1490) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2053, 24 pp. https://doi.org/10.2903/j.efsa.2011.2053

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011k. Scientific Opinion on the substantiation of health claims related to creatine and increase in physical performance during short-term, high intensity, repeated exercise bouts (ID 739, 1520, 1521, 1522, 1525, 1526, 1531, 1532, 1533, 1534, 1922, 1923, 1924), increase in endurance capacity (ID 1527, 1535), and increase in endurance performance (ID 1521, 1963) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(7):2303, 24 pp. https://doi.org/10.2903/j.efsa.2011.2303

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011l. Scientific Opinion on the substantiation of health claims related to bovine colostrum (ID 1472, 1473, 1474, 1475, 1476, 1889, 1890) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2048, 15 pp. https://doi.org/10.2903/j.efsa.2011.2048

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011m. Scientific Opinion on the substantiation of health claims related to l-β-hydroxy l-β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocaproic acid (KIC) and reduction of muscle tissue damage during exercise (ID 1577, 1584), increase in lean body mass (ID 1579, 1582, 1583), increase in muscle strength (ID 1578, 1583, 1587), increase in endurance performance (ID 1580, 1581), skeletal muscle tissue repair (ID 1586) and faster recovery from muscle fatigue after exercise (ID 1576, 1585) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2227, 23 pp. https://doi.org/10.2903/j.efsa.2011.2227

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011n. Scientific Opinion on the substantiation of health claims related to casein protein hydrolysates and growth or maintenance of muscle mass (ID 1498), increase in endurance performance (ID 660, 1497) and faster recovery from muscle fatigue after exercise (ID 660, 1497) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011; 9(6):2213, 15 pp. https://doi.org/10.2903/j.efsa.2011.2213

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012a. Scientific Opinion on Dietary Reference Values for protein. EFSA Journal 2012;10(2):2557, 66 pp. https://doi.org/10.2903/j.efsa.2012.2557

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012b. Scientific Opinion on the substantiation of a health claim related to citrulline-malate and faster recovery from muscle fatigue after exercise pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2012;10(5):2699, 13 pp. https://doi.org/10.2903/j.efsa.2012.2699

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012c. Guidance on the scientific requirements for health claims related to physical performance. EFSA Journal 2012;10(7):2817, 9 pp. https://doi.org/10.2903/j.efsa.2012.2817

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012d. Guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations. EFSA Journal 2012;10(3):2604, 11 pp. https://doi.org/10.2903/j.efsa.2012.2604

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2013. Scientific Opinion on the substantiation of a health claim related to glycaemic carbohydrates and recovery of normal muscle function (contraction) after strenuous exercise pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2013;11(10):3409, 10 pp. https://doi.org/10.2903/j.efsa.2013.3409

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014a. Scientific Opinion on the substantiation of a health claim related to citrulline-malate and faster recovery from muscle fatigue after exercise pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2014;12(5):3650, 11 pp. https://doi.org/10.2903/j.efsa.2014.3650

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014b. Scientific Opinion on the substantiation of a health claim related to beta-alanine and increase in physical performance during short-duration, high-intensity exercise pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2014;12(7):3755, 11 pp. https://doi.org/10.2903/j.efsa.2014.3755

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014c. Scientific Opinion on the substantiation of a health claim related to carbohydrate solutions and maintenance of physical performance during endurance exercise pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2014;12(10):3836, 8 pp. https://doi.org/10.2903/j.efsa.2014.3836

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016a. General scientific guidance for stakeholders on health claim applications. EFSA Journal 2016;14(1):4367, 38 pp. https://doi.org/10.2903/j.efsa.2016.4367
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016b. Scientific opinion on creatine in combination with resistance training and improvement in muscle strength: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2016;14(2):4400, 17 pp. https://doi.org/10.2903/j.efsa.2016.4400

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhäuser-Berthold M, Nowicka G, Pentieva K, Sjödin A, Stern M, Tomé D, Van Loveren H, Vinceti M, Willatts P, Martin A, Strain JJ, Heng L, Valtueña Martinez S and Siani A, 2017. Scientific and technical guidance for the preparation and presentation of a health claim application (Revision 2). EFSA Journal 2017;15(1):4680, 31 pp. https://doi.org/10.2903/j.efsa.2017.4680

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhäuser-Berthold M, Nowicka G, Pentieva K, Sjödin A, Stern M, Tomé D, Van Loveren H, Vinceti M, Willatts P, Martin A, Strain JJ and Siani A, 2018. Scientific Opinion on the carbohydrate solutions and contribute to the improvement of physical performance during a high-intensity and long-lasting physical exercise: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2018;16(3):5191, 17 pp. https://doi.org/10.2903/j.efsa.2018.5191

Fisher J and Smith D, 2012. Attempting to better define “intensity” for muscular performance: is it all wasted effort? European Journal of Applied Physiology, 112, 4183–4185; author reply 4187-4188.

Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC and Swain DP, 2011. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Medicine and Science in Sports and Exercise, 43, 1334–1359.

Howley ET, 2001. Type of activity: resistance, aerobic and leisure versus occupational physical activity. Medicine and Science in Sports and Exercise, 33, S364–S369; discussion S419-320.

Norton K, Norton L and Sadgrove D, 2010. Position statement on physical activity and exercise intensity terminology. Journal of Science and Medicine in Sport, 13, 496-502.

Winter EM, Abt G, Brookes FB, Challis JH, Fowler NE, Knudson DV, Knuttgen HG, Kraemer WJ, Lane AM, van Mechelen W, Morton RH, Newton RU, Williams C and Yeadon MR, 2016. Misuse of “Power” and Other Mechanical Terms in Sport and Exercise Science Research. Journal of Strength and Conditioning Research, 30, 292–300.

**Abbreviations**

1RM one repetition maximum  
BCAA branched-chain amino acids  
DOMS delayed-onset muscle soreness  
DRV Dietary Reference Values  
HBM β-hydroxy β-methylbutyrate monohydrate  
HRmax maximum heart rate  
HRR heart rate reserve  
KIC α-ketoisocaproic acid  
MVC maximum voluntary contraction  
NDA EFSA Panel on Nutrition, Novel Foods and Food Allergens  
RCTs randomised controlled trials  
RPE rating of perceived exertion  
SOD superoxide dismutase  
VO2max maximum oxygen consumption  
VO2R VO2 reserve
## Appendix A – Health claims on muscle function and physical performance evaluated by the EFSA NDA Panel

| Food constituent | Claimed effect                                                                 | Outcome          | Based on the essentiality of nutrients | Scope       | References                               |
|------------------|--------------------------------------------------------------------------------|------------------|----------------------------------------|-------------|------------------------------------------|
| ATP              | Maintenance of normal muscle function                                         | Unfavourable     | –                                      | Art. 13(1)  | EFSA NDA Panel (2011i)                   |
| β-alanine        | Increase in physical performance during short-term high-intensity exercise      | Unfavourable     | –                                      | Art. 13(1)  | EFSA NDA Panel (2010d)                   |
|                  | Increase in time to exhaustion                                                 | Unfavourable     | –                                      |             |                                          |
|                  | Increase in physical performance during short-duration, high-intensity exercise | Unfavourable     | –                                      | Art. 13(5)  | EFSA NDA Panel (2014b)                   |
| Bovine colostrum | Improvement in exercise performance when combined with regular training        | Unfavourable     | –                                      | Art. 13(1)  | EFSA NDA Panel (2011l)                   |
|                  | Increase in lean body mass when combined with resistance exercise              | Unfavourable     | –                                      |             |                                          |
|                  | Recovery following intense exercise                                            | Unfavourable     | –                                      |             |                                          |
| BCAA             | Growth or maintenance of muscle mass                                           | Unfavourable     | –                                      | Art. 13(1)  | EFSA NDA Panel (2010g)                   |
|                  | Attenuation of the decline in muscle power following exercise at high altitude | Unfavourable     | –                                      |             |                                          |
|                  | Faster recovery from muscle fatigue after exercise                            | Unfavourable     | –                                      |             |                                          |
|                  | Improvement of cognitive function after exercise                              | Unfavourable     | –                                      |             |                                          |
|                  | Reduction in perceived exertion during exercise                               | Unfavourable     | –                                      |             |                                          |
| β-hydroxy β-     | Reduction of muscle tissue damage during exercise                              | Unfavourable     | –                                      | Art. 13(1)  | EFSA NDA Panel (2011m)                   |
| methylbutyrate   | Increase in lean body mass                                                     | Unfavourable     | –                                      |             |                                          |
| monohydrate (HBM)| Increase in muscle strength                                                     | Unfavourable     | –                                      |             |                                          |
| alone or in      | Increase in endurance performance                                              | Unfavourable     | –                                      |             |                                          |
| combination with | Skeletal muscle tissue repair                                                  | Unfavourable     | –                                      |             |                                          |
| α-ketoisocaproic  | Faster recovery from muscle fatigue after exercise                             | Unfavourable     | –                                      |             |                                          |
| acid (KIC)       |                                                                               |                  |                                        |             |                                          |
| Caffeine         | Increase in physical performance during short-term high-intensity exercise     | Unfavourable     | –                                      | Art. 13(1)  | EFSA NDA Panel (2011j)                   |
|                  | Increase in endurance capacity                                                 | Favourable       | NO                                     |             |                                          |
|                  | Increase in endurance performance                                              | Favourable       | NO                                     |             |                                          |
|                  | Reduction in the rated perceived exertion/effort during exercise               | Favourable       | NO                                     |             |                                          |
| Calcium          | Maintenance of normal muscle function (contraction)                           | Favourable       | YES                                    | Art.13(1)   | EFSA NDA Panel (2009a)                   |
| Food constituent                             | Claimed effect                                                                 | Outcome     | Based on the essentiality of nutrients | Scope       | References                     |
|---------------------------------------------|--------------------------------------------------------------------------------|-------------|-----------------------------------------|-------------|--------------------------------|
| Carbohydrate solutions                      | Maintenance of physical performance during endurance exercise                 | Unfavourable| –                                       | Art. 13(5)  | EFSA NDA Panel (2014c)          |
|                                            | Improvement of physical performance during a high-intensity and long-lasting physical exercise | Favourable  | NO                                      | Art. 13(5)  | EFSA NDA Panel (2018)           |
| Carbohydrate-electrolyte solutions          | Reduction in rated perceived exertion/effort during exercise                | Unfavourable| –                                       | Art. 13(1)  | EFSA NDA Panel (2011h)          |
|                                            | Enhancement of water absorption during exercise                              | Favourable  | NO                                      | –           | EFSA NDA Panel (2011n)          |
| Casein protein hydrolysates                 | Growth or maintenance of muscle mass                                        | Unfavourable| –                                       | Art. 13(1)  | EFSA NDA Panel (2011n)          |
|                                            | Increase in endurance performance                                          | Unfavourable| –                                       | –           | EFSA NDA Panel (2011n)          |
|                                            | Faster recovery from muscle fatigue after exercise                           | Unfavourable| –                                       | –           | EFSA NDA Panel (2011n)          |
| Citruline malate                            | Faster recovery from muscle fatigue after exercise                           | Unfavourable| –                                       | Art. 13(5)  | EFSA NDA Panel (2012b, 2014a)   |
| Coenzyme Q10                                | Contribution to normal energy-yielding metabolism                           | Unfavourable| –                                       | Art. 13(1)  | EFSA NDA Panel (2010f)          |
|                                            | Increase in endurance capacity and/or endurance performance                 | Unfavourable| –                                       | –           | EFSA NDA Panel (2010f)          |
| Creatine                                    | Increase in physical performance during short-term, high intensity, repeated exercise bouts | Favourable  | NO                                      | Art. 13(1)  | EFSA NDA Panel (2011k)          |
|                                            | Increase in endurance capacity                                              | Unfavourable| –                                       | –           | EFSA NDA Panel (2011k)          |
|                                            | Improvement in muscle strength (in combination with resistance training)     | Favourable  | NO                                      | Art. 13(5)  | EFSA NDA Panel (2016b)          |
| L-carnitine                                 | Faster recovery from muscle fatigue after exercise                           | Unfavourable| –                                       | Art.13(1)   | EFSA NDA Panel (2011a)          |
|                                            | Skeletal muscle tissue repair                                                | Unfavourable| –                                       | –           | EFSA NDA Panel (2011a)          |
|                                            | Increase in endurance capacity                                              | Unfavourable| –                                       | –           | EFSA NDA Panel (2011a)          |
| L-carnosine                                 | Increase in muscle power                                                    | Unfavourable| –                                       | Art.13(1)   | EFSA NDA Panel (2011b)          |
|                                            | Increase in endurance capacity                                              | Unfavourable| –                                       | –           | EFSA NDA Panel (2011b)          |
| Glycaemic carbohydrates                     | Recovery of normal muscle function (contraction) after strenuous exercise    | Favourable  | YES                                     | Art.13(5)   | EFSA NDA Panel (2013)           |
| L-glutamine                                 | Growth or maintenance of muscle mass                                         | Unfavourable| –                                       | Art.13(1)   | EFSA NDA Panel (2011c)          |
|                                            | Faster restoration of muscle glycogen stores after strenuous exercise        | Unfavourable| –                                       | –           | EFSA NDA Panel (2011c)          |
|                                            | Skeletal muscle tissue repair                                                | Unfavourable| –                                       | –           | EFSA NDA Panel (2011c)          |
| Magnesium                                   | Maintenance of normal muscle function (contraction)                         | Favourable  | YES                                     | Art.13(1)   | EFSA NDA Panel (2009c)          |

Guidance for health claims on muscle function and physical performance
| Food constituent | Claimed effect                                | Outcome     | Based on the essentiality of nutrients | Scope | References                      |
|------------------|----------------------------------------------|-------------|-----------------------------------------|-------|----------------------------------|
| Potassium        | Maintenance of normal muscle function (contraction) | Favourable  | YES                                     | Art.13(1) | EFSA NDA Panel (2010h)  |
| Protein          | Growth or maintenance of muscle mass         | Favourable  | YES                                     | Art.13(1) | EFSA NDA Panel (2010a)  |
| Ribose           | Faster recovery from muscle fatigue after exercise | Unfavourable | –                                       | Art.13(1) | EFSA NDA Panel (2011d)  |
| Sodium           | Maintenance of normal muscle function (contraction) | Favourable  | YES                                     | Art.13(1) | EFSA NDA Panel (2011g)  |
| Sodium phosphate | Increase in endurance performance             | Unfavourable | –                                       | Art.13(1) | EFSA NDA Panel (2011f)  |
| Soy phosphatidyl choline | Faster recovery from muscle fatigue after exercise | Unfavourable | –                                       | Art.13(1) | EFSA NDA Panel (2010e)  |
| Superoxide dismutase (SOD) | Reduction of muscle fatigue during exercise | Unfavourable | –                                       | Art.13(1) | EFSA NDA Panel (2010b)  |
| Taurine          | Maintenance of normal cardiac function        | Unfavourable | –                                       | Art.13(1) | EFSA NDA Panel (2009b, 2011e) |
| Whey protein     | Growth or maintenance of muscle mass         | Unfavourable | –                                       | Art.13(1) | EFSA NDA Panel (2010c)  |
|                  | Increase in lean body mass during energy restriction and resistance training | Unfavourable | –                                       |       |                                 |
|                  | Reduction of body fat mass during energy restriction and resistance training | Unfavourable | –                                       |       |                                 |
|                  | Increase in muscle strength                  | Unfavourable | –                                       |       |                                 |
|                  | Increase in endurance capacity during the subsequent exercise bout after strenuous exercise | Unfavourable | –                                       |       |                                 |
|                  | Skeletal muscle tissue repair                | Unfavourable | –                                       |       |                                 |
|                  | Faster recovery from muscle fatigue after exercise | Unfavourable | –                                       |       |                                 |

BCAA: branched-chain amino acids.